ストックスクリーナーアプリを入手
9.90
4.99%
-0.52
アフターアワーズ：
9.90
前日終値:
$10.42
開ける：
$10.38
24時間の取引高:
215.90K
Relative Volume:
2.31
時価総額：
$329.40M
収益：
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.1988
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
-22.05%
1か月 パフォーマンス:
-12.85%
6か月 パフォーマンス:
-52.31%
1年 パフォーマンス:
-54.71%
1日の値動き範囲:
$9.5101
$10.53
1週間の範囲:
$9.5101
$13.10
52週間の値動き範囲:
$8.85
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
名前
Cartesian Therapeutics Inc
セクター
電話
301-348-8698
住所
7495 NEW HORIZON WAY, FREDERICK
RNAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.90 | 329.40M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | 開始されました | BTIG Research | Buy |
| 2024-08-06 | 開始されました | TD Cowen | Buy |
| 2024-07-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-04 | 開始されました | Oppenheimer | Outperform |
| 2024-05-24 | 開始されました | Mizuho | Buy |
| 2024-04-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-23 | 開始されました | Leerink Partners | Outperform |
| 2023-08-18 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | 繰り返されました | Needham | Buy |
| 2022-06-06 | 開始されました | SVB Leerink | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-01-26 | アップグレード | Mizuho | Neutral → Buy |
| 2020-10-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-10-01 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | ダウングレード | Stifel | Buy → Hold |
| 2020-04-28 | 開始されました | H.C. Wainwright | Buy |
| 2020-01-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-01-21 | 開始されました | William Blair | Outperform |
| 2018-06-27 | 開始されました | Janney | Buy |
| 2017-03-30 | 繰り返されました | UBS | Buy |
すべてを表示
Cartesian Therapeutics Inc (RNAC) 最新ニュース
Cartesian Therapeutics Reports Q1 2025 Financial Results - TipRanks
Needham Maintains Buy Rating on RNAC, Lowers Price Target | RNAC Stock News - GuruFocus
RNAC Reports Strong Q1 Revenue Exceeding Expectations | RNAC Stock News - GuruFocus
Cartesian Therapeutics Inc (RNAC) Q1 2025 Earnings: EPS Loss of $(0.68) Beats Estimate, Revenue Surpasses Forecast at $1.1 Million - GuruFocus
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Renaissance Technologies LLC Buys New Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27% - simplywall.st
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Awards to New Em - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Expands Clinical Team: 27,700 Shares Granted to New Biotech Experts - Stock Titan
Cartesian Therapeutics CTO transitions to consultant role By Investing.com - Investing.com India
Cartesian Therapeutics CTO transitions to consultant role - Investing.com
Cartesian Therapeutics CTO Transition to Consultant Role - TipRanks
SEC Form DEF 14A filed by Cartesian Therapeutics Inc. - Quantisnow
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLC - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.67 Consensus Target Price from Brokerages - Defense World
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - ADVFN
Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Shows Efficacy and Safety in Myasthenia Gravis in Phase 2 Study - CGTLive®
JPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
After-Market Momentum Builds For ASP Isotopes (ASPI) Amid Secondary Listing News - Stocks Telegraph
Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at HC Wainwright - Defense World
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock - Investing.com Australia
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock By Investing.com - Investing.com South Africa
HC Wainwright Reiterates Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - The AM Reporter
Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter
Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech
Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire
Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World
Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa
Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada
Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics Inc (RNAC) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):